Pipeline Programs - Setrusumab for Osteogenesis Imperfecta (OI) Phase 3 results were reported around the end of 2025, partnered with Ultragenyx, but neither study achieved the primary endpoint of reduction in AFR compared to placebo or bisphosphonates[8, 11] - Alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) activities are ongoing to support the initiation of Phase 3, following an agreement in principle on the primary endpoints[8] - Vantictumab for osteopetrosis is out-licensed to āshibio, with EU rights retained, and an IND is planned for H2 2026[8] Financial Status - The company has approximately $41 million in cash and cash equivalents as of December 31, 2025, providing a cash runway into mid-2027[8] Setrusumab Clinical Trial Results - In the Orbit study (Setrusumab vs placebo), 19.5% of patients met rescue criteria at 12 months, primarily due to fractures, with a larger number of placebo patients exiting the study[14] - In the Cosmic study (Setrusumab vs bisphosphonates), there was a 59% reduction in vertebral fractures on setrusumab (p=0.081), despite more severe type III/IV patients on setrusumab (65% setrusumab vs 54% IV-BP)[31] - Setrusumab patients in the Orbit study showed improvements in disease severity (PGIS) in peds/teens, as well as improvements in pain/comfort and sports/activity[20] Market Opportunities - Osteogenesis Imperfecta affects approximately 60,000 patients across the US & Europe[9] - Severe Alpha-1 Antitrypsin Deficiency affects an estimated 50,000 patients in North America and 60,000 in Europe[9] - Osteopetrosis has an incidence of 1 in 20,000 in North America and Europe, with onset typically in late childhood[9]

Membership and Growth - Total membership reached 275,300 as of January 1, 2026, reflecting a 30% Compound Annual Growth Rate (CAGR) since inception[16] - The company projects year-end 2026 membership to be in the range of 290,000 to 296,000[16,46] - From 2024 to Q3 2025, peers averaged 1% annual membership growth[36] - As of January 1, 2026, 80% of new members are new to MA, and 20% are MA plan switchers[47] - January 1 net Medicare Advantage enrollment growth in California was +23,800 (+84% YoY)[47] - January 1 net Medicare Advantage enrollment growth Ex-California was +41,500 (+23% YoY)[47] Financial Performance - The company's total revenue has grown from $127 million in 2014 to $3939 million in 2024[16] - The company raised YE adjusted EBITDA guidance from $48M to $94M at the midpoint from initial guidance to current guidance[52] - The company expects consensus adjusted EBITDA of $145M to be within FY 2026 guidance range[52] Quality and Cost Management - 100% of Alignment's members are in plans rated 4 stars or above, compared to 65% for the industry[40] - The company invests ~4% of medical expenses for at-risk members in employed clinical model[21] - The company has achieved superior growth while managing medical costs effectively, differentiating itself from peers who averaged a 1% annual membership growth and an annual increase in MBR of 160bps[36] Market Position - The company has less than 1% national market share and approximately 6% share in existing markets[53] - The MA market is projected to grow further over the next decade, with MA penetration reaching 58% in 2034[54]

Financial Performance and Guidance - Acadia reiterated its 2025 revenue guidance of $3280 million to $3300 million[12] - The company also reaffirmed its 2025 adjusted EBITDA guidance of $601 million to $611 million[12] - Acadia expects adjusted EPS for 2025 to be in the range of $194 to $204[12] - Weaker volume environment impacting recent cohort occupancy ramp[34] Operational Highlights and Expansion - Acadia is the 1 pure-play Behavioral Health (BH) provider in the US, treating over 82000 patients daily across its 4 service lines[16] - The company operates 277 facilities across the nation, including 59 acute facilities, 31 specialty facilities, 9 RTC facilities, and 178 CTC locations[16] - In 2025, Acadia added 1089 new beds but closed five facilities totaling 382 beds, resulting in a net increase of 707 beds[30] Strategic Initiatives and Challenges - The company is focused on setting the standard for quality across the industry while expanding access to behavioral healthcare[23] - Acadia faced challenges in 2025, including increased PLGL litigation costs, volume underperformance, and rate pressure, impacting adjusted EBITDA[32] - New facility openings represent >$200 million incremental EBITDA opportunity[37]

Financial Position and Runway - Beam had $1.25 billion in cash as of December 31, 2025, inclusive of $255.1 million proceeds from the Orbital acquisition[16] - The company's operating runway is expected into 2029, funding through risto-cel launch and execution of BEAM-302 pivotal development plan[16,60] Program Advancements and Regulatory Alignment - Beam achieved first human proof of concept for in vivo gene correction with BEAM-302 in 2025[17] - Alignment was reached with the FDA on a potential accelerated approval pathway for BEAM-302 in AATD, with primary endpoint expected to be based on AAT biomarkers evaluated over 12 months[27] - The company plans to submit the risto-cel BLA package as early as YE 2026[45,60] Clinical Data and Trial Updates - BEAM-302 Phase 1/2 trial has dosed >25 patients across cohorts to date, with updated clinical data expected by the end of first quarter 2026[25,60] - Initial clinical data for BEAM-301 is planned to be reported by YE 2026[31,60] - BEACON results for risto-cel in SCD show HbF levels >60% and HbS levels <40%, comparable to sickle trait, with resolution of anemia and normalized or improved markers of hemolysis and oxygen delivery[37] - At Day 28, BEAM-302 showed mean total AAT in circulation at 12.4µM, mean % change in Z-AAT at -78%, and corrected M-AAT reached >90% of total circulating AAT[24] Strategic Initiatives - Beam completed a $500 million financing and runway extension into 2029[17] - The company intends to pursue an accelerated approval pathway for BEAM-302 based on FDA feedback to date[26]

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is advancing zorevunersen as a potential disease-modifying therapy for Dravet Syndrome[9] - Phase 3 study (EMPEROR) enrollment is expected to complete in Q2 2026 with data readout in mid-2027 to support NDA[12, 38] - Approximately 330 patients have been identified globally for the EMPEROR study, with ~60 in screening and ~60 randomized[12, 39] - Data from ongoing OLE studies show continuing improvements in cognition and behavior over 36 months[24] - Zorevunersen demonstrated significant reduction in major motor seizure frequency at 6 months compared to natural history data, with an 8248% reduction compared to a 2043% reduction in the natural history group (P=00181)[26] - In OLE studies, 86% of patients experienced CSF protein elevation, classified as a TEAE in 45%[31] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - A Phase 1 study of STK-002 for ADOA has been initiated in the UK and Europe[11] Financial Status and Collaboration - Stoke Therapeutics had approximately $3917 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with funding anticipated into 2028[12] - A strategic collaboration with Biogen exists for the development and commercialization of zorevunersen, with Biogen holding exclusive commercialization rights outside of the US, Canada, and Mexico[48] - The Biogen collaboration includes $165 million upfront, shared development costs, and potential milestone payments of $385 million[49] Market Opportunity - There are approximately 38,000 patients with Dravet syndrome across 7 major markets[40, 44]

Financial Performance and Growth - Harmony Biosciences anticipates net revenue between $1 billion and $1.04 billion for 2026[16] - The company's revenue has grown consistently year-over-year, with $714.7 million in 2024, $868 million in 2025, and projected growth into 2026[52] - WAKIX net revenue has shown significant growth from $160 million in 2020 to over $1 billion projected for 2026[15] Pitolisant Franchise Strategy - The company is focused on growing the WAKIX franchise, extending it with Pitolisant GR, and expanding it with Pitolisant HD[8] - Pitolisant GR has the potential to extend the pitolisant franchise with utility patents filed to 2044[9] - Pitolisant HD has the potential to expand the pitolisant patient base into new indications[9] Pipeline Development - A Phase 1 clinical PK data for BP1.15205, a potential best-in-class Orexin 2 Receptor (OX2R) Agonist, is anticipated in mid-2026[42] - Topline data from ongoing global Phase 3 trials for EPX-100 in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) are anticipated in 1H 2027[45, 47] - The company submitted an NDA for Pitolisant GR in Q2 2026, with an anticipated PDUFA date in Q1 2027[31] Market Opportunity - There are approximately 170,000 people living with narcolepsy in the U S, with over 50% undiagnosed[22]

Financial Performance & Growth - Amneal's net revenues increased from $1.6 billion in 2019 to $3.0 - $3.1 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of +7% to +11%[14] - Adjusted EBITDA grew from $339 million in 2019 to $675 million - $685 million in 2025, with a CAGR of +8% to +9%[14] - Operating cash flow increased significantly from $2 million in 2019 to an estimated $300 million - $330 million in 2025[14] - Total company revenue for FY 2024 was $2.794 billion, with a +9% historical growth rate (2020-2024 CAGR) and a high single-digit growth projection[18] Portfolio & Pipeline - The company has a growing portfolio of 280+ affordable medicines across complex dosage forms[10] - The company has 69 pending ANDAs (Abbreviated New Drug Applications), with 64% being non-oral solids[14] - The company has 44 pipeline products, with 95% being non-oral solids[14] - The company has 3 commercial biosimilars and 5 biosimilars in the pipeline[14] Market & Strategy - The company is targeting the GLP-1/Peptides market, which is projected to grow from $26 billion in 2025 to $50 billion in 2030[16] - The company expects $300-500 million in U S peak sales for CREXONT® for Parkinson's Disease[19] - The company expects $50-100 million in U S peak sales for Brekiya® for migraine[24]

Financial Performance and Outlook - Elanco expects organic constant currency revenue growth starting in 2025[10] - The company anticipates adjusted EBITDA growth starting in 2026[10] - Elanco projects over $1 billion in total free cash flow from 2026 to 2028[10] - The company aims to reduce net leverage to below 3x in 2027 and further towards 20x-25x[10] - Elanco expects innovation to deliver $11 billion in revenue in 2026, compared to $840-$880 million in 2025[90] Innovation and Pipeline - Elanco's innovation engine is expected to generate $840-$880 million in revenue in 2025[34] - The "Big 6" products are projected to drive $11 billion in innovation revenue in 2026[39] - The company anticipates 5-6 potential blockbuster approvals between 2026 and 2031, with peak sales exceeding $2 billion[10, 61, 90] - Elanco's "Next Wave" innovation portfolio includes over 15 projects across 8 innovation spaces[58, 59] Market and Industry Trends - The animal health industry is projected to grow from $42 billion to $60 billion[11] - The pet health industry is a $17 billion market experiencing mid-single-digit to high-single-digit growth[16] - The farm animal health industry is a $25 billion market with low-single-digit to mid-single-digit growth[17] Elanco Ascend and Cost Savings - Elanco Ascend is expected to generate approximately $200-$250 million in adjusted EBITDA savings by 2030, net of inflation and reinvestment[71, 90] - The company anticipates approximately $25 million in savings in 2026, $60 million in 2027, and $130 million in cash cost[90]

Business Overview - The company has nine medicines on the market driving revenue growth[4] - Two co-owned medicines are TIVDAK® (tisotumab vedotin) and EPKINLY® /TEPKINLY® (epcoritamab)[4] - The company is targeting <3x gross leverage by 2027E[6] Pipeline and Potential Launches - Three late-stage assets are positioned for potential 2027 launches[4] - Epkinly® (Lymphoma) has a peak annual sales potential of >$3 Billion[8] - Rina-S® (Gyn-Onc) has a peak annual sales potential of >$2 Billion[8] - Petosemtamab (HNSCC) has a multi-$Billion peak annual sales potential[8] - Up to six registrational readouts are expected in 2026, enabling 2027 launches[13] Financial Performance and Projections - In 2024, revenue was $3121 million[28] - In 2024, net profit was $1133 million[28] - Darzalex sales in 2024 were $1167 billion and are projected to reach $203 billion by 2030[15]

Powering how Americans save, spend, and invest in health Copyright © 2026 HealthEquity, Inc. All rights reserved. | HealthEquity does not provide legal, tax or financial advice. Investor presentation 1 #1 HSA provider 1 in 4 HSAs in the US are with us +100k clients 200+ Network partners 10.1M HSAs +6% YoY $34.4B HSA assets +15% YoY 17.3M Total Accounts +5% YoY Source: HealthEquity key metrics reported as of Oct 31, 2025. #1 HSA by number of accounts based on 2025 Midyear Devenir HSA report, October 9, 2025. ...